PubRank
Search
About
BMS-936558 (MDX-1106) In Subjects With Advanced/Metastatic Clear-Cell Renal Cell Carcinoma (RCC)
Clinical Trial ID NCT01354431
PubWeight™ 80.60
‹?›
🔗 Visit the ClinicalTrials.gov page for NCT01354431
Top papers
Rank
Title
Journal
Year
PubWeight™
‹?›
1
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.
N Engl J Med
2012
52.99
2
Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer.
Clin Cancer Res
2013
3.48
3
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
J Clin Oncol
2014
2.78
4
Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.
JAMA Oncol
2016
2.75
5
Breathing new life into immunotherapy: review of melanoma, lung and kidney cancer.
Nat Rev Clin Oncol
2013
2.64
6
The Impact of Tonsillectomy upon the Risk of Oropharyngeal Carcinoma Diagnosis and Prognosis in the Danish Cancer Registry.
Cancer Prev Res (Phila)
2015
2.17
7
Human cancer immunotherapy with antibodies to the PD-1 and PD-L1 pathway.
Trends Mol Med
2014
1.59
8
Antibody-based immunotherapy of cancer.
Cell
2012
1.35
9
New immunotherapies targeting the PD-1 pathway.
Trends Pharmacol Sci
2015
1.02
10
Clinical impact of checkpoint inhibitors as novel cancer therapies.
Drugs
2014
0.99
11
Role of immunotherapy for renal cell cancer in 2011.
J Natl Compr Canc Netw
2011
0.91
12
Subverting the B7-H1/PD-1 pathway in advanced melanoma and kidney cancer.
Cancer J
2014
0.88
13
Targeting PD-1/PD-L1 in the treatment of metastatic renal cell carcinoma.
Ther Adv Urol
2015
0.88
14
Impact of baseline and nadir neutrophil index in non-small cell lung cancer and ovarian cancer patients: Assessment of chemotherapy for resolution of unfavourable neutrophilia.
J Transl Med
2013
0.85
15
PD-1 as an emerging therapeutic target in renal cell carcinoma: current evidence.
Onco Targets Ther
2014
0.85
16
PD-1 blockade in renal cell carcinoma: to equilibrium and beyond.
Cancer Immunol Res
2014
0.85
17
Immunotherapy in Metastatic Renal Cell Carcinoma: A Comprehensive Review.
Biomed Res Int
2015
0.83
18
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Immunotherapy
2014
0.81
19
Evolving Concepts: Immunity in Oncology from Targets to Treatments.
J Oncol
2015
0.81
20
Tivozanib in the treatment of renal cell carcinoma.
Biologics
2013
0.80
21
Influence of tumors on protective anti-tumor immunity and the effects of irradiation.
Front Oncol
2013
0.79
22
Cellular and molecular immunology of lung cancer: therapeutic implications.
Expert Rev Clin Immunol
2014
0.79
23
Melanoma and immunotherapy bridge 2015 : Naples, Italy. 1-5 December 2015.
J Transl Med
2016
0.77
24
Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma.
ESMO Open
2016
0.77
25
Harnessing the PD-1 pathway in renal cell carcinoma: current evidence and future directions.
BioDrugs
2014
0.76
26
New clinical advances in immunotherapy for the treatment of solid tumours.
Immunology
2015
0.76
27
An update on current management of advanced renal cell cancer, biomarkers, and future directions.
Ann Cancer Res
2015
0.76
28
Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of renal cell carcinoma.
J Immunother Cancer
2016
0.75
Next 100